�InNexus
Biotechnology Inc., (TSX: IXS.V; OTC Bulletin Board: IXSBF)
(hypertext transfer protocol://www.ixsbio.com), a drug development company commercializing the
next generation of monoclonal antibodies based on its Dynamic Cross Linking
(DXL(TM)) engineering, announced that it has launched a large scale
primate sketch of DXL625 (CD20), the company's lead program.
"We are beginning a study in cynomolgus monkeys of DXL625, an antibody
directed against the B-cell marker CD20 and enhanced in potency with our
DXL(TM) technology," aforesaid Thomas Kindt, Ph.D., Chief Scientific Officer.
"The try out is designed to value toxicity and pharmokinetics of our
product and to measure B-cell depletion and recovery in this hierarch
species. This study, which takes multiple months to complete and is office of
our drug maturation plan will generate data moving us toward human
clinical test testing with DXL625."
"Our scientific team has made steady progress in the rapid development
of our first preclinical candidate, DXL625 for the prospective
